At present, all the semi-annual reports of domestic IVD related listed companies in 2020 have been disclosed. Against the backdrop of the global COVID-19 epidemic, Shenzhen New Industries Biomedical Engineering Co., LTD., which was officially listed on the Gem of Shenzhen Stock Exchange on May 12, 2020, performed well. During the reporting period, the company realized 97,0101,600 yuan of revenue, an increase of 31.06% over the same period last year. The total profit was 55,3,286,800 yuan, up 40.77% over the same period of last year; The net profit attributable to shareholders of the listed company is 47,5729,800 yuan, up 40.57% from the same period last year.

Under the influence of coVID-19, Snibe Co.,Ltd. still achieved 31.06% revenue growth, and the profit growth rate was even higher than the revenue growth rate of more than 40%. Such outstanding achievements, in addition to the company's own efforts, the market demand for testing reagents, especially the large demand for testing reagents in overseas markets, is also an important factor. This is mainly due to the substantial increase in overseas sales revenue.

As can be seen from the above table, the domestic operating income of Snibe Co.,Ltd. in the reporting period decreased by 23.67% compared with the same period of last year, while the overseas operating income increased by 242.41% year-on-year, achieving explosive growth. The reason is that it cannot be separated from the stable overseas customer base.

By the end of the reporting period, the global cumulative installed capacity of all types of automatic chemilescent immune analyzers in Snibe Co.,Ltd. has exceeded 14,400, and nearly 7,000 instruments have been sold in 145 countries overseas. It can be found from the above table that the main profit driver of Snibe Co.,Ltd. is reagents, whose gross profit margin reaches 91.99%. After users buy and install instruments, they are bound to consume testing reagents repeatedly. In addition, after the outbreak of COVID-19, Snibe Co.,Ltd. actively organized the research and development team, and became the first company in China to launch COVID-19 chemiluminescence detection reagent and obtain CE certification, providing antibody detection reagent continuously for many countries in Europe and America with severe epidemic. The customer base of instruments and supporting software and the r&d and upgrading of reagents together promoted the company's large sales of COVID-19 antibody detection reagents in the European Union, the Americas and other countries with severe epidemic in the second quarter, so as to overcome the headwinds and forge ahead.

According to Marketsand Markets, the size of the global immunodiagnostic market will reach us $20.109 billion in 2018, which is the largest sub-industry in the in vitro diagnostic industry market. It is expected to maintain a compound growth rate of 6.1% and grow to US $27.15 billion by 2023, with North America, Europe and Asia as the main core Markets.

The in vitro diagnostic market in China is composed of subdivided fields such as immunodiagnosis, biochemical diagnosis, hematology and body fluids, instant testing and molecular diagnosis. Among them, the immunodiagnostic market is the largest, accounting for about 31% of the domestic in vitro diagnostic market, while biochemical diagnosis ranks the second, accounting for about 20% of the domestic in vitro diagnostic market.

Shenzhen New Industry Biomedical Engineering Co., Ltd. is mainly engaged in the research and development, production, sales and service of in vitro diagnostic products. Since its establishment, it has always been customer-oriented and market-oriented, providing better products and services through continuous product and technological innovation. The company's products are mainly used to provide disease prevention, diagnosis, treatment monitoring, prognostic observation, health status evaluation and genetic disease prediction of diagnostic information.

At present, new industry biology has established four major technology r&d platforms, namely, nano-magnetic microsphere, reagent key raw materials, instrument research and development, and reagent research and development. In the leading immunodiagnostic product line, it has 8 automatic chemiluminescence immunoassay instruments and 126 supporting reagents, covering tumor markers, thyroid, gonad, metabolism, liver fibrosis, infectious diseases and other detection items. In the actively expanding biochemical diagnostic product line, it has 4 automatic biochemical analytical instruments and 45 auxiliary reagents, which cover renal function, liver function, special proteins, lipids and other testing items.